Drug Profile
Research programme: anti TIGIT antibodies - Seagen
Alternative Names: TIGIT antibodies - SeagenLatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Cascadian Therapeutics
- Developer Seagen
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 08 Oct 2020 Seattle Genetics is now called Seagen